[caption id="attachment_69467" align="aligncenter" width="500"]
Photo by Christina Morillo[/caption]
Every clinical trial produces mountains of data. From patient enrollment logs and lab results to adverse event reports and protocol deviations, clinical data is the backbone of every decision made during drug or device development. Yet, collecting data is only the beginning — it’s how that data is managed, validated, and interpreted that determines a study’s success.
In the age of decentralized trials, real-time analytics, and global regulatory oversight, the importance of reliable clinical data management can’t be overstated. High-quality data doesn’t just support regulatory submissions — it protects patient safety, ensures compliance, and strengthens confidence in results.
Why Is Clinical Data Management No Longer Just a Technical Task?
Gone are the days when data management was treated as an afterthought or a purely technical role. Today, it’s central to trial strategy. From the very beginning of a study, data management professionals are involved in shaping case report forms (CRFs), planning how endpoints will be measured, and ensuring systems are in place to capture data accurately and securely.
This shift in thinking is due to the increasing complexity of trial protocols, the rise in remote data capture tools, and the growing pressure from regulators for traceable, auditable datasets. Sponsors and CROs alike are realizing that data management is no longer an isolated function — it’s the foundation of trial integrity.
What Does a Modern Clinical Trial Data Management Service Include?
A robust
clinical trial data management service goes far beyond database design. It encompasses an ecosystem of systems, people, and processes designed to ensure that every data point collected is clean, consistent, and ready for analysis.
Typical services include:
- CRF design tailored to protocol endpoints
- Electronic Data Capture (EDC) system configuration
- Real-time data monitoring and discrepancy resolution
- Medical coding using standard dictionaries (e.g., MedDRA, WHO Drug)
- Query management and investigator communication
- Data cleaning, validation, and database lock support
The goal is simple: to transform complex, multi-source data into a reliable and statistically sound dataset that regulators can trust — and that sponsors can use to make decisions.
Dr. Donofry[/caption]
Shannon D. Donofry Ph.D.
Behavioral Scientist
B.A.Sc. in psychology/neuroscience
University of Pittsburgh-Pittsburgh Campus;
Ph.D, University of Pittsburgh-Pittsburgh Campus
[caption id="attachment_70207" align="alignleft" width="125"]
Dr. Rancaño[/caption]
Katherine M. Rancaño, Ph.D
Associate Policy Researcher
RAND
MedicalResearch.com: What is the background for this study?
Response: GLP-1 medications were first used to help people with diabetes manage their blood sugar. Lately, they’ve become popular for helping people lose weight, too. Because of this, a lot more people have started using them. In our study, we asked over 8,000 adults from across the country about their use of GLP-1 medications and any side effects they had.
L. Levi[/caption]
Liran Levi, PhD student
Faculty of Medicine at Hebrew University
MedicalResearch.com: What is the background for this study?
Response: Motivated behavior is driven by a group of brain regions called collectively the reward system. This neural system is at the heart of every decision we make about our actions - it integrates information about the world and decides whether to perform a behavior or not based on the predicted reward/benefit. The key molecule in this process is dopamine - whenever we perform a behavior that provides a reward dopamine is released in the reward system and reinforces this behavior. Drugs of abuse exploit this system - they cause abnormally high levels of dopamine, and thus force the reward system to seek drugs constantly, even after prolonged withdrawal. From a neurobiological perspective, that is how we view substance dependence - the reward system drives people to seek for the reward.
Dr. Campanella[/caption]
Gabriele Campanella, PhD
Assistant Professor
Windreich Department of Artificial Intelligence and Human Health
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study?
Response: Lung cancer is the most lethal cancer in the US. Lung adenocarcinoma (LUAD) is the most common form of lung cancer with an incidence of over 100k per year in the US. EGFR mutations are common driver mutations in LUAD, and importantly, these mutations can be targeted by TKI therapy, which has high response rates. Because of this, EGFR testing via NGS (Next Generation Sequencing) is considered mandatory by guidelines for any LUAD diagnosis.
In high-resource settings, rapid EGFR testing is done while waiting for confirmation via NGS. This is because NGS takes about 2 weeks on average, while the rapid testing has a median TAT of 2 days. Early treatment decisions could be made based on the rapid test results. Rapid tests have some important drawbacks, most notably, it exhausts tissue. In lung cancer, tissue is scarce in the first place, and up to 25% of cases, after rapid testing there is not enough tissue for NGS. In those circumstances, patients have to be biopsied again, which adds unnecessary risk for the patient. Even worse, in some cases, the NGS is never done. A non-tissue-exhaustive computational biomarker could be used instead of the tissue-based rapid test.
Dr. Steenson[/caption]
Dr. Simon Steenson PhD
Postdoctoral Research Associate
Department of Nutritional Sciences
King’s College London
MedicalResearch.com: What is the background for this study?
Response: Chronic constipation is something that can be embarrassing, but it affects 1 in 10 people globally. It has a big impact on people’s quality of life and treating constipation has substantial costs for the healthcare system. Dried fruits are recommended for managing constipation, but there are very few studies that have actually tested whether following this advice is helpful. To fill this gap in our knowledge, we completed the largest clinical trial to date to see whether dried fruits and fruit juices could benefit constipation symptoms.
Dr. Corley[/caption]
Douglas Corley, MD, PhD
Chief Research Officer, The Permanente Medical Group
Kaiser Permanente, Northern California
MedicalResearch.com: What is the background for this study?
Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician. 
Dr. Klonoff[/caption]
Parita K. Ray[/caption]
Prof. El GHOCH[/caption]
MedicalResearch.com Interview with:
Prof. Marwan EL GHOCH
